GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Phreesia Inc (NYSE:PHR) » Definitions » Days Sales Outstanding

Phreesia (Phreesia) Days Sales Outstanding : 54.97 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Phreesia Days Sales Outstanding?

Phreesia's average Accounts Receivable for the three months ended in Jan. 2024 was $57.2 Mil. Phreesia's Revenue for the three months ended in Jan. 2024 was $95.0 Mil. Hence, Phreesia's Days Sales Outstanding for the three months ended in Jan. 2024 was 54.97.

The historical rank and industry rank for Phreesia's Days Sales Outstanding or its related term are showing as below:

PHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.43   Med: 58.57   Max: 62.24
Current: 54.09

During the past 7 years, Phreesia's highest Days Sales Outstanding was 62.24. The lowest was 52.43. And the median was 58.57.

PHR's Days Sales Outstanding is ranked worse than
57.34% of 640 companies
in the Healthcare Providers & Services industry
Industry Median: 46.205 vs PHR: 54.09

Phreesia's Days Sales Outstanding declined from Jan. 2023 (56.53) to Jan. 2024 (54.97).


Phreesia Days Sales Outstanding Historical Data

The historical data trend for Phreesia's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phreesia Days Sales Outstanding Chart

Phreesia Annual Data
Trend Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Days Sales Outstanding
Get a 7-Day Free Trial 55.87 62.24 59.22 59.89 58.57

Phreesia Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.53 55.09 52.12 49.73 54.97

Competitive Comparison of Phreesia's Days Sales Outstanding

For the Health Information Services subindustry, Phreesia's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phreesia's Days Sales Outstanding Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Phreesia's Days Sales Outstanding falls into.



Phreesia Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Phreesia's Days Sales Outstanding for the fiscal year that ended in Jan. 2024 is calculated as

Days Sales Outstanding (A: Jan. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jan. 2023 ) + Accounts Receivable (A: Jan. 2024 )) / count ) / Revenue (A: Jan. 2024 )*Days in Period
=( (51.458 + 62.88) / 2 ) / 356.299*365
=57.169 / 356.299*365
=58.57

Phreesia's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

Days Sales Outstanding (Q: Jan. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Oct. 2023 ) + Accounts Receivable (A: Jan. 2024 )) / count ) / Revenue (A: Jan. 2024 )*Days in Period
=( (51.593 + 62.88) / 2 ) / 95.005*365 / 4
=57.2365 / 95.005*365 / 4
=54.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phreesia  (NYSE:PHR) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Phreesia Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Phreesia's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Phreesia (Phreesia) Business Description

Traded in Other Exchanges
Address
1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, USA, 19803
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
Executives
Balaji Gandhi officer: Chief Financial Officer PHREESIA, INC., 1521 CONCORD PIKE, SUITE 301, PMB 221, WILMINGTON DE 19803
Allison C Hoffman officer: General Counsel & Secretary 315 EAST 68TH STREET, NEW YORK NY 10065
Amy Beth Vanduyn officer: SVP, Human Resources C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Chaim Indig director, officer: Chief Executive Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Michael J. Davidoff officer: See Remarks C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
David Linetsky officer: SVP, Life Sciences C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Evan Roberts officer: Chief Operating Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Janet Gunzburg officer: Principal Accounting Officer BANKRATE, INC., 477 MADISON AVENUE, SUITE 430, NEW YORK NY 10022
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
Gillian Munson director C/O XO GROUP INC., 195 BROADWAY, 25TH FLOOR, NEW YORK NY 10007
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Randy Rasmussen officer: Chief Financial Officer PHREESIA, INC., 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC 27601
Ramin Sayar director 305 MAIN STREET, REDWOOD CITY CA 94063
Michael Weintraub director C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Edward L Cahill 10 percent owner C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 200, WALTHAM MA 02453